(Q37853657)

24 August 2017

1 reference

title

Bacteriophages for the treatment of Pseudomonas aeruginosa infections (English)

1 reference

24 August 2017

Pseudomonas aeruginosa

0 references

1 reference

D R Harper

1

1 reference

PubMed ID

21410851

24 August 2017

M C Enright

series ordinal

2

1 reference

24 August 2017

18 April 2011

1 reference

Journal of Applied Microbiology

24 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

24 August 2017

111

1 reference

24 August 2017

1

1 reference

24 August 2017

1-7

1 reference

Bacteriophage isolation from human saliva

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Pseudomonas aeruginosa cytotoxin as a pathogenicity factor in a systemic infection of leukopenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

High abundance of viruses found in aquatic environments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Why chronic wounds will not heal: a novel hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Bacteriophages of Pseudomonas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

STREPTOMYCIN treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Filamentous phages linked to virulence of Vibrio cholerae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Isolation and characterization of temperate bacteriophages of Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Shiga toxin-producing Escherichia coli: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Bacteriophages: an appraisal of their role in the treatment of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Evolution of MRSA during hospital transmission and intercontinental spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Aminoglycoside antibiotics induce bacterial biofilm formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Persister cells and tolerance to antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Pseudomonas aeruginosa: a formidable and ever-present adversary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

The SaPIs: mobile pathogenicity islands of Staphylococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Frequent emergence and limited geographic dispersal of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Nongenetic individuality in the host-phage interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Treatment of experimental infections of mice with bacteriophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Therapeutic use of bacteriophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Pseudomonas aeruginosa - a phenomenon of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Bacteriophages as therapeutic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Future antibiotics scenarios: is the tide starting to turn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa ; a preliminary report of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2672.2011.05003.X

10.1111/J.1365-2672.2011.05003.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21410851